SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity through B Cell Antigen Presentation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39943808.
- Also identified by DOI 10.1021/acsnano.4c15113 and PMC identifier 12664698.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current neoantigen cancer vaccines activate T cell immunity through dendritic cell/macrophage-mediated antigen presentation. It is unclear whether incorporating B cell-mediated antigen presentation into current neoantigen vaccines could enhance CD4/CD8 T cell immunity to improve their anticancer efficacy. We developed SARS-CoV-2 B cell epitope-guided neoantigen peptide/mRNA cancer nanovaccines (B<sub>SARS</sub>T<sub>NeoAg</sub>Vax) to improve anticancer efficacy by enhancing tumor-specific CD4/CD8 T cell antitumor immunity through B cell-mediated antigen presentation. B<sub>SARS</sub>T<sub>NeoAg</sub>Vax cross-linked with B cell receptor, promoted SARS-CoV-2 B cell-mediated antigen presentation to tumor-specific CD4 T cells, increased tumor-specific follicular/nonfollicular CD4 T cells, and enhanced B cell-dependent tumor-specific CD8 T cell immunity. B<sub>SARS</sub>T<sub>NeoAg</sub>Vax achieved superior efficacy in melanoma, pancreatic, and breast cancer models compared with the current neoantigen vaccines. Our study provides a universal platform, SARS-CoV-2 B epitope-guided neoantigen nanovaccines, to improve anticancer efficacy against various cancer types by enhancing CD4/CD8 T cell antitumor immunity through viral-specific B cell-mediated antigen presentation.
Medical subject headings
- CD8-Positive T-Lymphocytes
- SARS-CoV-2
- Epitopes, B-Lymphocyte
- Antigen Presentation
- Cancer Vaccines
- CD4-Positive T-Lymphocytes
- B-Lymphocytes
- COVID-19
- Antigens, Neoplasm